Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

Area of Science:

• Rare diseases
• Histiocytosis
• Immunology

Background:

• Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis.
• It involves multiple organs including the heart, lungs, CNS, bones, and kidneys.
• Kidney involvement leads to renal failure in approximately 30% of cases.

Purpose of the Study:

• To report a case of Erdheim-Chester disease (ECD) with severe cardiac and renal involvement.
• To evaluate the efficacy of anakinra in treating this patient.

Main Methods:

• The study presents a case report of an elderly patient diagnosed with ECD.
• Treatment involved anakinra, an interleukin-1 receptor antagonist.

Main Results:

• The patient with severe cardiac and kidney involvement showed successful treatment outcomes with anakinra.
• This suggests anakinra's therapeutic potential for ECD.

Conclusions:

• Anakinra is a promising treatment for Erdheim-Chester disease, particularly in cases with significant cardiac and renal compromise.
• Further research is warranted to confirm anakinra's efficacy in a broader ECD patient population.